Industry News
Research, Science & Manufacturer Updates
A recent study has found that people infected with H1N1 swine flu produce antibodies that are protective against a variety of flu strains, which may help scientists eventually develop a universal vaccine.
A new cancer test is sensitive enough to spot a single cancer cell among a billion healthy cells, which may offer a better way to screen for the disease than methods currently used.
Examining issues regarding SCIG billing, coding and Medicare claims, along with questions about certification of homebound patients and products with new reimbursement codes.
Imperial College London scientists have identified a protein, called IRF5, that acts as a “master switch” in certain white blood cells that either stimulate or suppress inflammation.
Researchers at the University of South Carolina found that THC, the chemical behind the “high” of cannabis, fueled the production of a flood of cells thought to weaken the body’s built-in defenses.
As of April 2011, many cuts to healthcare spending are being proposed and expected.
Health Canada has approved Fluad, a seasonal flu vaccine manufactured by Novartis for adults aged 65 years and older. Fluad is the first seasonal flu vaccine in Canada to contain an adjuvant.
The House Judiciary Committee is working to pass medical tort reform legislation.
Researchers in Japan have found that one inhaled dose of Daiichi Sankyo Co.Ltd.’s CS8958 (or laninamivir) worked better than Tamiflu to keep mice alive when infected with a normally deadly dose of H5N1 avian influenza.
The U.S. Food and Drug Administration (FDA) has approved Benlysta (belimumab) to treat patients with active autoantibody positive lupus (systemic lupus erythematosus) who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives and non steroidal anti-inflammatory drugs.